InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Carboat post# 138522

Friday, 08/30/2013 7:06:32 PM

Friday, August 30, 2013 7:06:32 PM

Post# of 345997

Have the strong retail hands considered that rather than having outsmarted the street and being amoung the elite in the know about Bavi taking over soc in oncology, that the pros are playing them? That a nice set of true believing strong retail hands is a reliable place to dump shares.



You are off your game tonight....

An operations such as that would have all sorts of fluffy PR articles from various internet sites so it can actually boose the price up for those dumped shares you talk about.

An operation such as that would "never" get first night posters calling for the company to go bankrupt and Bavi a placebo

An operation such as that simply doesn't exist here. Peregrine employees have purchased shares at a rate of 10 to 1 from just 2 years ago.

The only operation going on here is Big Pharma trying to capture Bavi for as little $$$ as possible... those plans backfired : )

Imagine: Peregrine about to announce a partner last year when "clear evidence of dose switching" emerges, think its possible that the Big Pharma sitting across the table had two options in mind in how this would play out. A good chess player would always think ahead to that 3rd alternative but maybe they were willing to risk it all.

1) BP thought Peregrine would settle for cheap $$$ and not make a big scene as they simply would not announce "coding discrepancy results" and be forced to start all over and with what money? a reverse split... ATM... maybe a new BOD ?

2)BP thought Peregrine would not settle for cheap $$$ and after announcing "coding discrepancies" the stock falls and Big Pharma is standing by ready for some action

...... 3) BP did not expect Peregrine to:

- "NOT" settle for cheap money,
- Go directly to the FDA and report everything,
- Receive Phase III Cotara go ahead,
- Salvage the Phase IIb NSCLC
- Receive Phase III NSCLC go ahead,
- ..all this while the targeting of PS is becoming apparently clear as the target and being verified as a biomarker--- even BMS 777607 had some playdates with PS : ) ...
--- and most importantly: hold onto "CLEAR EVIDENCE OF DOSE SWITCHING" for a rainy day to be exchanged for a free approval of some sort : )


Everyone have a good weekend... its going to be a beautiful weekend! : )

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News